Conventional treatment with epoetin (a synthetic form of human erythropoietin that promotes red-blood cell production) to manage anaemia in chronic kidney disease needs frequent administrations (at least weekly), changes of dose, and close monitoring of haemoglobin concentrations.
Dr Nathan Levin, Renal Research Institute, New York, USA, and colleagues compared the effectiveness of a long-acting erythropoieses-stimulating agent variant of epoetin (methoxy polyethylene glycol-epoetin beta), given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemoglobin control in haemodialysis patients. The study was designed so that all patients (673 in total, from North America and Europe) received conventional epoetin treatment initially; after four weeks a third of individuals were given methoxy polyethylene glycol-epoetin beta every two weeks, another third given methoxy polyethylene glycol-epoetin beta every four weeks, with the remaining third continuing to receive conventional epoetin treatment throughout the trial..
Haemoglobin concentrations were recorded at baseline, throughout the study, and at a final assessment which took place around a mean of 42 weeks after baseline. The main result of the study showed how individuals given methoxy polyethylene glycol-epoetin beta either fortnightly or every four weeks had no statistically significant change in haemoglobin concentrations compared with those who remained on mainly a three-times-a-week regimen of epoetin treatment throughout the study. Adverse outcomes were minimal and similar between the epoetin and methoxy polyethylene glycol-epoetin beta treatment arms.
Dr Levin comments: “Errors with medication occur at an unacceptably high rate of 45%. Extrapolation to about 246000 haemodialysis patients in the USA suggests that 111000 dose errors could happen every month. Treatment with methoxy poly-ethylene glycol-epoetin beta every 4 weeks would need only 13 doses per year, compared with 52–156 doses with conventional epoetin, and would therefore allow fewer opportunities for error. Since our findings show that haemoglobin can be controlled in all dialysis patients with methoxy polyethylene glycol-epoetin beta given every 4 weeks, we advise that this drug should be introduced as an option to epoetin for simplified anaemia management.”
In an accompanying Comment, Dr Rowan Walker, Royal Melbourne Hospital and Monash University Alfred Hospital, Melbourne, Australia, and Dr Giovanni Strippoli, University of Sydney, Australia, and Mario Negri Sud Consortium, Chieti, Italy, say: “Before we can concur on a precise clinical role for this molecule, we need to explore issues other than simply the non-inferiority with other epoetins to reach certain unvalidated surrogates. Different does and molecular characteristics of epoetins may affect patient-level endpoints, independent of achieved haemoglobin. When these issues are examined, we might be truly confident that a newer molecule is non-inferior to existing ones.”
Tony Kirby | alfa
Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University
Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences